

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person* <u>Michor Franziska</u>			2. Issuer Name and Ticker or Trading Symbol <u>RECURSION PHARMACEUTICALS, INC. [RRRX]</u>			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner Officer (give title below) Other (specify below)		
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 11/20/2024			6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person		
41 S. RIO GRANDE STREET			4. If Amendment, Date of Original Filed (Month/Day/Year)					
(Street) SALT LAKE CITY UT 84101								
(City)	(State)	(Zip)						

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Class A Common Stock	11/20/2024		A		30,618	A	(1)	30,618	D	
Class A Common Stock	11/20/2024		A		15,335 ⁽²⁾	A	\$0	45,953	D	
Class A Common Stock	11/20/2024		A		17,694 ⁽³⁾	A	\$0	63,647	D	
Class A Common Stock	11/20/2024		A ⁽⁴⁾		41,390	A	\$0	105,037	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Stock Option (Right to Buy)	\$6.59	11/20/2024		A		30,670		(5)	05/02/2033	Class A Common Stock	30,670	(6)	30,670	D	
Stock Option (Right to Buy)	\$7.34	11/20/2024		A		15,286		(7)	05/16/2033	Class A Common Stock	15,286	(8)	15,286	D	
Stock Option (Right to Buy)	\$6.64	11/20/2024		A		17,694		(9)	05/14/2034	Class A Common Stock	17,694	(10)	17,694	D	
Stock Option (Right to Buy)	\$6.04	11/20/2024		A		82,781		(11)	11/21/2034	Class A Common Stock	82,781	\$0	82,781	D	

Explanation of Responses:

- (1) Received in exchange for [] ordinary shares of Exscientia plc ("Exscientia") in connection with the acquisition of the entire issued and to be issued share capital of Exscientia by Recursion Pharmaceuticals, Inc. ("Recursion") on November 20, 2024 (the "Transaction"). The last closing price on The Nasdaq Stock Market prior to the effective time of the Transaction of (a) the American Depositary Shares ("ADSs") representing ordinary shares of Exscientia was \$4.84 per ADS, and (b) Recursion's Class A common stock was \$6.27 per share.
- Represents restricted stock units ("RSUs") that were exchanged in connection with the Transaction, each RSU representing the right to receive one share of Class A common stock of Recursion. The RSUs vest in equal quarterly installments beginning on November 3, 2024 and continuing through May 3, 2026, subject to the Reporting Person continuing to be a service provider through the applicable vesting dates.
- Represents RSUs that were exchanged in connection with the Transaction, each RSU representing the right to receive one share of Class A common stock of Recursion. The RSUs will vest on May 15, 2025, subject to the Reporting Person continuing to be a service provider through the applicable vesting date.
- Represents a grant of restricted stock units automatically granted pursuant to Recursion's Outside Director Compensation Policy. The restricted stock units will vest as to 1/3rd of the shares subject to the award on the first three anniversaries of November 20, 2024, subject to the Reporting Person continuing to be a service provider through the applicable vesting dates.
- Options vest and become exercisable in equal quarterly installments over a three year period beginning May 3, 2023, subject to the Reporting Person continuing to be a service provider through the applicable vesting dates.
- Received in the Transaction in exchange for a share option to acquire 39,683 Exscientia ordinary shares for \$5.09 per share.
- Options vest and become exercisable on May 17, 2024, subject to the Reporting Person continuing to be a service provider through the applicable vesting date.
- Received in the Transaction in exchange for a share option to acquire 19,778 Exscientia ordinary shares for \$5.67 per share.
- Options vest and become exercisable on May 15, 2025, subject to the Reporting Person continuing to be a service provider through the applicable vesting date.

10. Received in the Transaction in exchange for a share option to acquire 22,894 Exscientia ordinary shares for \$5.13 per share.

11. Represents a grant of options automatically granted pursuant to Recursion's Outside Director Compensation Policy. The shares subject to this option will vest and become exercisable as to 1/3rd of the shares subject to the award on the first three anniversaries of November 20, 2024, subject to the Reporting Person continuing to be a service provider through the applicable vesting dates.

Remarks:

Jonathan D. Golightly,
attorney-in-fact

11/22/2024

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.